<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">TCM</journal-id><journal-title-group><journal-title>Traditional Chinese Medicine</journal-title></journal-title-group><issn pub-type="epub">2166-6067</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/TCM.2017.62018</article-id><article-id pub-id-type="publisher-id">TCM-20704</article-id><article-categories><subj-group subj-group-type="heading"><subject>TCM20170200000_20578606.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  原人参二醇及Compound K抑制肝细胞肝癌的作用及机制
  The Inhibitory Effect of Protopanoxadiol and Compound K on Hepatocellular Carcinoma and the Underlying Mechanisms
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>春蕾</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>宋</surname><given-names>海燕</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>许</surname><given-names>阳贤</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>季</surname><given-names>光</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>上海中医药大学附属龙华医院普外科</addr-line></aff><aff id="aff2"><addr-line>上海中医药大学附属龙华医院脾胃病研究所</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>jiliver@vip.sina.com(季光)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>05</month><year>2017</year></pub-date><volume>06</volume><issue>02</issue><fpage>104</fpage><lpage>109</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   中晚期肝癌及术后复发转移性肝癌目前仍然缺乏有效治疗手段。原人参二醇(protopanoxadiol, PPD)及人参皂苷Compound K是二醇型人参皂苷在体内的代谢产物。近年来多项研究发现这两种天然产物可通过诱导细胞凋亡、抑制细胞增殖、抑制血管生成、抑制转移等机制对多种肿瘤发挥抑瘤效应。其中对肝细胞肝癌的作用研究较多，抑癌效果尤为突出。本文就近年来PPD及Compound K抗肝细胞肝癌的作用和相关机制研究进行系统综述，以期有助于开发出有效治疗肝癌的天然药物。 There is still no effective treatment available for advanced liver cancer or the recurrence and me-tastasis after surgical resection. Protopanoxadiol (PPD) and ginsenoside Compound K are the me-tabolites of protopanaxadiol-type ginsenosides in vivo. In recent years, a number of studies have found that these two kinds of natural products could play a role of tumor suppression through in-ducing cell apoptosis, inhibiting cell proliferation, inhibiting angiogenesis and limiting tumor cell metastasis. Among them, there are many studies focusing on the effect of PPD or Compound K on hepatocellular carcinoma (HCC), in which the anti-cancer effect is prominent. This paper reviews the recent studies on the role of PPD/Compound K in HCC and the related mechanisms, in order to ben-efit the development of new effective natural medicine to treat HCC. 
  
 
</p></abstract><kwd-group><kwd>肝细胞肝癌，原人参二醇，Compound K, Hepatocellular Carcinoma</kwd><kwd> Protopanoxadiol</kwd><kwd> Compound K</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>原人参二醇及Compound K抑制肝细胞肝癌的作用及机制<sup> </sup></title><p>张春蕾<sup>1</sup>，宋海燕<sup>1</sup>，许阳贤<sup>2</sup>，季光<sup>1*</sup></p><p><sup>1</sup>上海中医药大学附属龙华医院脾胃病研究所，上海</p><p><sup>2</sup>上海中医药大学附属龙华医院普外科，上海</p><disp-formula id="hanspub.20704-formula48"><graphic xlink:href="http://html.hanspub.org/file/12-2270194x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2017年5月8日；录用日期：2017年5月23日；发布日期：2017年5月26日</p><disp-formula id="hanspub.20704-formula49"><graphic xlink:href="http://html.hanspub.org/file/12-2270194x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>中晚期肝癌及术后复发转移性肝癌目前仍然缺乏有效治疗手段。原人参二醇(protopanoxadiol, PPD)及人参皂苷Compound K是二醇型人参皂苷在体内的代谢产物。近年来多项研究发现这两种天然产物可通过诱导细胞凋亡、抑制细胞增殖、抑制血管生成、抑制转移等机制对多种肿瘤发挥抑瘤效应。其中对肝细胞肝癌的作用研究较多，抑癌效果尤为突出。本文就近年来PPD及Compound K抗肝细胞肝癌的作用和相关机制研究进行系统综述，以期有助于开发出有效治疗肝癌的天然药物。</p><p>关键词 :肝细胞肝癌，原人参二醇，Compound K</p><disp-formula id="hanspub.20704-formula50"><graphic xlink:href="http://html.hanspub.org/file/12-2270194x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2017 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="http://image.hanspub.org:8080\Html/htmlimages\1-2890033x\e70a10f1-7c93-45ea-9603-062237856e4b.png" /><img src="http://image.hanspub.org:8080\Html\htmlimages\1-2890033x\e898c85e-ffc4-45c9-b817-14224a4d6960.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>肝癌是最常见的恶性肿瘤之一，全球每年近 80万人死于肝癌，位居癌症死因的第三位。在我国由于肝炎和肝炎转肝硬化的病人众多，每年肝癌发病率及病死率均占全球一半以上，肝癌居癌症死因的第2位。其中，90%以上肝癌是肝细胞肝癌(hepatocellular carcinoma, HCC)。恶性程度高、手术切除或肝移植后复发转移率高、缺乏有效化疗和靶向药物，使HCC迄今仍然预后很差 [<xref ref-type="bibr" rid="hanspub.20704-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.20704-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.20704-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.20704-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.20704-ref5">5</xref>] 。</p><p>中医药治疗肿瘤尤其对于中晚期肿瘤，采用“去邪扶正”的治则，近年来临床实践和研究表明这种中医疗法可联合局部手术、放化疗应用起到增效减毒和改善患者生活质量的功效，也可单独使用发挥抑瘤作用。但传统中药复方成分复杂，药效和质控不稳定，药效物质及机制不明确，难以被国际同行接受。从中合理有效地筛检出有效组分或成分研究是突破中药开发应用瓶颈的研究思路。</p><p>人参是常用的中医去邪扶正药物，长期实验结果表明，人参有显著抗癌作用 [<xref ref-type="bibr" rid="hanspub.20704-ref6">6</xref>] 。人参主要生物活性成分为人参皂苷，是四环三萜类化合物，包括原人参二醇型、原人参三醇型和齐墩果酸型，其中原人参二醇型皂苷具有较强抗肿瘤作用 [<xref ref-type="bibr" rid="hanspub.20704-ref7">7</xref>] 。药物代谢结果表明，原人参二醇型皂苷在体内经肠道菌群代谢降解为：次苷-20-O-β-D-吡喃葡萄糖苷-20(S)-原人参二醇(20-O-beta-d-glucopyranosyl-20(S)-protopanaxadiol, GPD)，又被研究者称为Compound K，或苷元—原人参二醇(protopanoxadiol, PPD)入血，是其体内主要代谢物和药效实体 [<xref ref-type="bibr" rid="hanspub.20704-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.20704-ref9">9</xref>] 。PPD也可由人参属的三七、西洋参皂苷或者绞股蓝属植物提取物反应获得。近年来的多项体内体外实验显示，PPD和Compound K具有较强的抗多种肿瘤活性，包括胃癌、乳腺癌、肝癌、卵巢癌、结肠癌、黑色素瘤等 [<xref ref-type="bibr" rid="hanspub.20704-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.20704-ref9">9</xref>] ，对肿瘤细胞有很强细胞毒性，并有抑制细胞增殖、诱导细胞分化和凋亡、调节免疫等作用 [<xref ref-type="bibr" rid="hanspub.20704-ref10">10</xref>] - [<xref ref-type="bibr" rid="hanspub.20704-ref15">15</xref>] 。二者对肝细胞肝癌的效果尤为显著，能有效抑制肝癌细胞增殖、诱导凋亡，并可提高抗肝癌药物的肿瘤抑制作用，增效减毒。明确药理机制有利于药物的开发应用，近年来科研人员同时对PPD和Compound K的抗癌作用相关分子机制也进行了深入研究。本文概述二者在HCC中的生物药理作用及机制，以期促进其在HCC治疗中的开发应用。</p></sec><sec id="s4"><title>2. PPD/Compound K调控凋亡途径，诱导细胞凋亡</title><p>PPD/Compound K可诱导肝癌细胞的凋亡，其作用主要通过三种基本途径：由细胞表面的死亡受体如Fas和肿瘤坏死因子受体家族引发的膜受体途径；由多种应激条件、化学试剂或药物所起始的线粒体途径；内质网应激活化半胱天冬蛋白酶Caspase-12进而导致凋亡的内质网应激途径。</p><p>研究表明，PPD可抑制SMMC-7721细胞裸鼠异种移植瘤生长，发挥抗肿瘤作用 [<xref ref-type="bibr" rid="hanspub.20704-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.20704-ref17">17</xref>] 。体外实验发现PPD呈剂量依赖性地抑制SMMC-7721细胞的增殖并诱导细胞凋亡，进一步发现其上调Caspase-3活性，诱导凋亡小体出现 [<xref ref-type="bibr" rid="hanspub.20704-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.20704-ref17">17</xref>] 。Compound K能够上调人肝癌细胞MHCC97-H的Fas、Fas配体(FasL)表达及Bax/Bcl-2比例，抑制Akt的磷酸化，通过调节Fas死亡受体和线粒体介导的通路诱导MHCC97-H细胞凋亡 [<xref ref-type="bibr" rid="hanspub.20704-ref18">18</xref>] 。但也有研究发现，在人肝癌细胞HepG2中，Compound K虽可抑制Fas/FasL表达，上调可溶性Fas配体(sFasL)的表达，但阻断Fas受体并没有影响Compound K诱导的细胞凋亡，提示Fas/FasL途径只是Compound K诱导细胞凋亡的途径之一 [<xref ref-type="bibr" rid="hanspub.20704-ref19">19</xref>] 。</p><p>Liu等研究证实，Compound K可以破坏线粒体膜电位(Δψm)，导致细胞色素C的释放，诱导细胞凋亡 [<xref ref-type="bibr" rid="hanspub.20704-ref20">20</xref>] 。用Compound K干预人肝癌细胞株MHCC97-H，细胞染色显示亚二倍体凋亡率增加。进一步研究发现Compound K致线粒体膜电位降低，诱导DNA剪切损伤。明艳林等用Compound K干预人肝癌细胞株 SMMC-7721、HepG2、MHCC97-H，同样发现Compound K增加细胞周期中亚二倍体峰，促进DNA 降解梯形条带的形成，线粒体跨膜电位崩溃，增加Caspase-9/Caspase-3的表达，表明Compound K可促进肝癌细胞凋亡，从而发挥其抗HCC活性 [<xref ref-type="bibr" rid="hanspub.20704-ref21">21</xref>] 。Song等研究发现，Compound K通过上调抑癌基因P53表达，诱导细胞核内的Bid剪切并转移至线粒体，促使细胞色素C从线粒体释放，从而介导线粒体凋亡途径促使肝癌细胞凋亡 [<xref ref-type="bibr" rid="hanspub.20704-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.20704-ref23">23</xref>] 。Cho等也报道Compound K促进凋亡作用通过激活caspases-3、caspases-8和caspases-9，破坏线粒体膜电位，释放细胞色素C和Smac/DIABLO，Bid和Bax易位到线粒体表面，并下调Bcl-2和Bcl-xL的表达实现 [<xref ref-type="bibr" rid="hanspub.20704-ref24">24</xref>] 。</p><p>近来研究发现过度内质网应激可启动细胞凋亡，前者可特异性激活Caspase-12，进一步活化Caspase-3等下游效应蛋白酶,最终导致细胞凋亡。在人肝癌细胞HepG2中，PPD通过内外源性途径诱导细胞凋亡，激活死亡受体5以及Caspase-3、Caspase-8和Caspase-9的活性，并上调与内质网应激相关分子的表达。Guo等研究发现PPD可通过上调与内质网应激相关的蛋白和基因，使PPD治疗的细胞出现巨大的细胞质空泡化以及内质网的形态变化，从而抑制HepG2 细胞的生长，并诱导其凋亡 [<xref ref-type="bibr" rid="hanspub.20704-ref25">25</xref>] 。</p></sec><sec id="s5"><title>3. PPD/Compound K调控细胞周期，抑制细胞增殖</title><p>PPD阻滞肝癌细胞周期于G0/G1期，抑制肝癌细胞增殖。Mochizuki 等研究证实PPD使细胞产生明显的G1期阻滞现象，可能给抑癌基因提供了作用的靶点，如p53蛋白即是通过将细胞周期阻滞于G1期，对损伤DNA进行修复，当修复失败时诱导细胞凋亡 [<xref ref-type="bibr" rid="hanspub.20704-ref26">26</xref>] 。Compound K可将肝癌细胞SMMC-7721阻滞在G0/G1期，从而抑制SMMC-7721增殖发挥其抗肝癌作用 [<xref ref-type="bibr" rid="hanspub.20704-ref27">27</xref>] 。Ming等研究发现，Compound K以时间和剂量依赖方式能明显抑制肝癌细胞BEL-7402增殖，流式检测发现Compound K可将细胞周期阻滞在G0/G1期，进一步诱导细胞收缩、膜泡化、染色质降解等细胞凋亡特征 [<xref ref-type="bibr" rid="hanspub.20704-ref28">28</xref>] 。在人肝癌细胞MHCC97-H中，Compound K同样将细胞周期阻滞在G1期，从而抑制细胞增殖 [<xref ref-type="bibr" rid="hanspub.20704-ref18">18</xref>] 。</p></sec><sec id="s6"><title>4. PPD/Compound K抑制血管形成和HCC转移</title><p>论肿瘤细胞转移是造成绝大多数癌症患者死亡的原因，而肿瘤诱导的新生血管生成是肿瘤生长与转移最重要的原因之一 [<xref ref-type="bibr" rid="hanspub.20704-ref29">29</xref>] 。其中，内皮细胞增殖在血管新生中起着非常重要的作用，而PPD可以剂量依赖的方式抑制人脐静脉内皮细胞增殖 [<xref ref-type="bibr" rid="hanspub.20704-ref30">30</xref>] 。此外，肝癌血管生成受诸多血管生成因子如血管内皮生长因子(vascular endothelial growth factor, VEGF)、碱性成纤维细胞生长因子(basic fibroblast growth factor, bFGF)等的影响，这些细胞因子的表达可被PPD所抑制，进而抑制肿瘤血管的生成 [<xref ref-type="bibr" rid="hanspub.20704-ref31">31</xref>] [<xref ref-type="bibr" rid="hanspub.20704-ref32">32</xref>] 。秦俊杰等研究也发现PPD通过抑制肝癌间质血管密度，抑制肿瘤血管的形成，使肿瘤细胞的增殖活性下降，从而抑制了肿瘤生长 [<xref ref-type="bibr" rid="hanspub.20704-ref33">33</xref>] 。</p><p>Ming等通过体内外实验发现Compound K可以抑制NF-κB通路的激活，使体外肝癌细胞的集落形成、黏附和侵袭能力减弱，同时也使得体内自发肝癌的转移性生长得到抑制。并且Compound K也能够通过抑制VEGF、bFGF的分泌来抑制肝癌细胞的侵袭转移 [<xref ref-type="bibr" rid="hanspub.20704-ref34">34</xref>] 。</p></sec><sec id="s7"><title>5. PPD/Compound K协同抗癌药物作用</title><p>P-糖蛋白(P-glycoprotein, P-gp)表达增加是肿瘤耐药的一个重要原因。PPD可通过阻断P-gp的活性，从而显著提高化疗药物的肿瘤抑制作用，显示与化疗药物抗癌活性具有协同效应 [<xref ref-type="bibr" rid="hanspub.20704-ref35">35</xref>] 。明艳林等将Compound K与常用抗肝癌药物环磷酰胺(Cytoxan, CTX)、5-氟尿嘧啶(5-FU)、顺铂(cDDP)联合处理肝癌细胞Bel-7402、SMMC-7721，发现Compound K与CTX联合用药后对肝癌细胞Bel-7402、SMMC-7721的增殖抑制作用明显增强，具有化疗协同、增敏作用；与5-FU联合用药后对两种细胞的抑制作用仅有相加效果，与cDDP联合对SMMC-7721具有轻微协同效果 [<xref ref-type="bibr" rid="hanspub.20704-ref36">36</xref>] 。</p></sec><sec id="s8"><title>6. 小结</title><p>原人参二醇型皂苷代谢物PPD及Compound K具有广泛的生物学作用，对包括HCC在内的多种肿瘤的药效作用已经被多项研究证实，药理机制研究也取得一定进展。其抗肝癌作用主要通过诱导细胞凋亡、抑制细胞增殖、抑制血管生成从而抑制转移等来实现，另外可提高其它化疗药物的抗肿瘤活性、改善肿瘤耐药，在其它肿瘤研究中还发现PPD有激活体内免疫系统、促进活性氧的产生活化AMPK/JNK诱导自噬等对抗肿瘤的作用 [<xref ref-type="bibr" rid="hanspub.20704-ref37">37</xref>] [<xref ref-type="bibr" rid="hanspub.20704-ref38">38</xref>] 。PPD及Compound K有望开发成治疗HCC的新型药物，但迄今多数研究仍然局限于体外实验或小鼠皮下成瘤实验，二者对于其它多种HCC细胞、动物肝脏原位肿瘤的作用以及临床实验研究有待后续开展。另外由于HCC发生发展的分子生物学机制的复杂性及天然药物的多靶点性，PPD及Compound K抗肝癌的机制也尚需更多更深入的探讨。</p></sec><sec id="s9"><title>基金项目</title><p>国家自然科学基金(81573894, 81202667)；中西医结合人才计划(ZY3-RCPY-4-2014)。</p></sec><sec id="s10"><title>文章引用</title><p>张春蕾,宋海燕,许阳贤,季光. 原人参二醇及Compound K抑制肝细胞肝癌的作用及机制The Inhibitory Effect of Protopanoxadiol and Compound K on Hepatocellular Carcinoma and the Underlying Mechanisms[J]. 中医学, 2017, 06(02): 104-109. http://dx.doi.org/10.12677/TCM.2017.62018</p></sec><sec id="s11"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.20704-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">(2014) Global Battle against Cancer Won’t Be Won with Treatment Alone—Effective Prevention Measures Urgently Needed to Prevent Cancer Crisis. Central European Journal of Public Health, 22, 23, 28.</mixed-citation></ref><ref id="hanspub.20704-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">梁宏元, 卢再鸣. 原发性肝癌综合介入治疗现状与困惑[J]. 临床肝胆病杂志, 2016(1): 44-48.</mixed-citation></ref><ref id="hanspub.20704-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">杨婉婷, 侯恩存. 原发性肝癌治疗的研究进展[J]. 现代肿瘤医学, 2016, 24(21): 3495-3499.</mixed-citation></ref><ref id="hanspub.20704-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, A.X. (2012) Molecularly Targeted Therapy for Advanced Hepatocellular Carcinoma in 2012: Current Status and Future Perspectives. Seminars in Oncology, 39, 493-502.&lt;br&gt; https://doi.org/10.1053/j.seminoncol.2012.05.014</mixed-citation></ref><ref id="hanspub.20704-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Personeni, N., Rimassa, L., Pressiani, T., et al. (2013) Molecular Determinants of Outcome in Sorafenib-Treated Patients with Hepatocellular Carci-noma. Journal of Cancer Research and Clinical Oncology, 139, 1179-1187.  
&lt;br&gt;https://doi.org/10.1007/s00432-013-1429-x</mixed-citation></ref><ref id="hanspub.20704-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Yun, T.K., Kim, S.H. and Lee, Y.S. (1995) Trial of a New Medium-Term Mod-el Using Benzo(a)pyrene Induced Lung Tumor in Newborn Mice. Anticancer Research, 15, 839-845.</mixed-citation></ref><ref id="hanspub.20704-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Huang, Y.C., Chen, C.T., Chen, S.C., et al. (2005) A Natural Compound (Ginsenoside Re) Isolated from Panax ginseng as a Novel Angiogenic Agent for Tissue Regeneration. Pharmaceutical Research, 22, 636-646.  
&lt;br&gt;https://doi.org/10.1007/s11095-005-2500-3</mixed-citation></ref><ref id="hanspub.20704-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Lee, S.J., Ko, W.G., Kim, J.H., et al. (2000) Induction of Apoptosis by a Novel Intestinal Metabolite of Ginseng Saponin via Cytochrome c-Mediated Activation of Caspase-3 Protease. Biochemical Pharmacology, 60, 677-685.</mixed-citation></ref><ref id="hanspub.20704-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">张虹, 付雯雯, 徐华丽, 等. 20(s)-原人参二醇、人参皂苷Rh2及人参皂苷Rg3抗肿瘤作用的对比[J]. 中国老年学杂志, 2014(17): 4911-4913.</mixed-citation></ref><ref id="hanspub.20704-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">郭亚雄, 刘艳波, 李德龙, 等. 20(s)-原人参二醇对前列腺癌RM-1细胞的生长抑制作用及其机制[J]. 吉林大学学报(医学版), 2010, 36(2): 349-353.</mixed-citation></ref><ref id="hanspub.20704-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">许宏, 杨佳卉, 杨景丽. 原人参二醇对人肺腺癌A549细胞作用的meta分析[J]. 甘肃科技, 2016, 32(4): 135-137.</mixed-citation></ref><ref id="hanspub.20704-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Tawab, M.A., Bahr, U., Karas, M., et al. (2003) Degradation of Ginsenosides in Humans after Oral Administration. Drug Metabolism &amp; Disposition, 31, 1065-1071. &lt;br&gt;https://doi.org/10.1124/dmd.31.8.1065</mixed-citation></ref><ref id="hanspub.20704-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Bae, E.A., Choo, M.K., Park, E.K., et al. (2002) Metabolism of Ginsenoside R(c) by Human Intestinal Bacteria and Its Related Antiallergic Activity. Biological &amp; Pharmaceutical Bulletin, 25, 743-747. &lt;br&gt;https://doi.org/10.1248/bpb.25.743</mixed-citation></ref><ref id="hanspub.20704-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Dong, H.J., Jiang, B.H., Han, Y., et al. (2010) Transformation of Compound K from Saponins in Leaves of Panaxnotoginseng by Immobilized β-Glucanase. Chinese Herbal Medicines, 2, 1044-1047.</mixed-citation></ref><ref id="hanspub.20704-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">刘娜, 朴虎日, 李宁, 等. 原人参二醇及其衍生物的化学与抗癌活性研究进展[J]. 中国药物化学杂志, 2008, 18(5): 384-388.</mixed-citation></ref><ref id="hanspub.20704-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">孟庆国, 衣松涛, 何杰, 等. 20(S)-原人参二醇及20(S)-原人参三醇新衍生物的设计、合成及体外抗肿瘤活性测定[C]//中国药学会. 创新药物及新品种研究、开发学术研讨会论文集: 2006年卷. 烟台: 中国药学会, 2006: 133-139.</mixed-citation></ref><ref id="hanspub.20704-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">张锐, 徐华丽, 于小风, 等. 20(S)-原人参二醇对SMMC-7721细胞体内外作用的研究[J]. 中国药理学通报, 2008, 24(11): 1504-1508.</mixed-citation></ref><ref id="hanspub.20704-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Zheng, Z.Z., Ming, Y.L., Chen, L.H., et al. (2014) Compound K-Induced Apoptosis of Human Hepatocellular Carcinoma MHCC97-H Cells in Vitro. Oncology Reports, 32, 325-331.</mixed-citation></ref><ref id="hanspub.20704-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Oh, S.H., Yin, H.Q. and Lee, B.H. (2004) Role of the Fas/Fas Ligand Death Receptor Pathway in Ginseng Saponin Metabolite-Induced Apoptosis in Hepg2 Cells. Archives of Pharmacal Research, 27, 402-406.  
&lt;br&gt;https://doi.org/10.1007/BF02980081</mixed-citation></ref><ref id="hanspub.20704-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Liu, X., Kim, C.N., Yang, J., et al. (1996) Induction of Apoptotic Program in Cell-Free Extracts: Requirement for dATP and Cytochrome c. Cell, 86, 147-157.&lt;br&gt; https://doi.org/10.1016/S0092-8674(00)80085-9</mixed-citation></ref><ref id="hanspub.20704-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">明艳林, 郑志忠, 陈良华, 等. 人参皂苷IH901抗肝癌生长及其侵袭转移的作用机理[J]. 中国科学: 生命科学, 2011, 41(3): 219-225.</mixed-citation></ref><ref id="hanspub.20704-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Song, G., Chen, G.G., Yun, J.P., et al. (2009) Association of p53 with Bid Induces Cell Death in Response to Etopo-side Treatment in Hepatocellular Carcinoma. Current Cancer Drug Targets, 9, 871-880.  
&lt;br&gt;https://doi.org/10.2174/156800909789760302</mixed-citation></ref><ref id="hanspub.20704-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Song, G., Guo, S., Wang, W., et al. (2010) Intestinal Metabolite Compound K of Ginseng Saponin Potently Attenuates Metastatic Growth of Hepatocellular Carcinoma by Augmenting Apoptosis via a Bid-Mediated Mitochondrial Pathway. Journal of Agricultural &amp; Food Chemistry, 58, 12753-12760. &lt;br&gt;https://doi.org/10.1021/jf103814f</mixed-citation></ref><ref id="hanspub.20704-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Cho, S.H., Chung, K.S., Choi, J.H., et al. (2009) Compound K, a Metabolite of Ginseng Saponin, Induces Apoptosis via Caspase-8-Dependent Pathway in HL-60 Human Leukemia Cells. BMC Cancer, 9, 449.</mixed-citation></ref><ref id="hanspub.20704-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, G.Y., Li, Y.W., Tse, A.K.W., et al. (2011) 20(S)-Protopanaxadiol, a Metabolite of Ginsenosides, Induced Cell Apoptosis through En-doplasmic Reticulum Stress in Human Hepatocarcinoma HepG2 Cells. European Journal of Pharmacology, 668, 88-98.</mixed-citation></ref><ref id="hanspub.20704-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Mochi-zuki, M., Yoo, Y.C., Matsuzawa, K., et al. (1995) Inhibitory Effect of Tumor Metastasis in Mice by Saponins, Ginsenoside-Rb2, 20(R)- and 20(S)-Ginsenoside-Rg3, of Red Ginseng. Biological &amp; Pharmaceutical Bulletin, 18, 1197-1202.&lt;br&gt; https://doi.org/10.1248/bpb.18.1197</mixed-citation></ref><ref id="hanspub.20704-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Ming, Y.L., Song, G., Chen, L.H., et al. (2007) Anti-Proliferation and Apoptosis Induced by a Novel Intestinal Metabolite of Ginseng Saponin in Human Hepatocellular Carcinoma Cells. Cell Biology International, 31, 1265-1273.  
&lt;br&gt;https://doi.org/10.1016/j.cellbi.2007.05.005</mixed-citation></ref><ref id="hanspub.20704-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Ming, Y.L., Zheng, Z.Z., Chen, L.H., et al. (2007) Apoptosis Induced by a Novel Intestinal Metabolite of Ginseng Saponin in Human Hepatocellular Carcinoma BEL-7402 Cells. Chinese Traditional &amp; Herbal Drugs, 38, 1511-1514.</mixed-citation></ref><ref id="hanspub.20704-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Saiki, I. (2007) In Vivo Anti-Metastatic Action of Ginseng Saponins Is Based on Their Intestinal Bacterial Metabolites after Oral Administration. Journal of Ginseng Research, 31, 1-13.&lt;br&gt; https://doi.org/10.5142/JGR.2007.31.1.001</mixed-citation></ref><ref id="hanspub.20704-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Usami, Y., Liu, Y.N., Lin, A.S., et al. (2008) Antitumor Agents. 261. 20(S)-Protopanaxadiol and 20(S)-Protopanaxa- triol as Antiangiogenic Agents and Total Assignment of (1)H NMR Spectra. Journal of Natural Products, 71, 478-481.  
&lt;br&gt;https://doi.org/10.1021/np070613q</mixed-citation></ref><ref id="hanspub.20704-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">冷吉燕, 付军, 王继萍. 20(s)-原人参二醇对肝癌血管内皮生长因子及碱性成纤维细胞生长因子蛋白表达的影响[J]. 临床肝胆病杂志, 2008, 24(1): 42-43.</mixed-citation></ref><ref id="hanspub.20704-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">张国成, 秦俊杰, 冷吉燕. 20(S)-原人参二醇抑制肝癌血管内皮生长因子及其基因的表达[J]. 中国老年学杂志, 2006, 26(7): 945-946.</mixed-citation></ref><ref id="hanspub.20704-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">秦俊杰, 杨艳秋, 李颖新, 等. 20(S)-原人参二醇对肝癌间质血管密度和肿瘤细胞增殖活性的影响[J]. 临床肝胆病杂志, 2006, 22(4): 260-261.</mixed-citation></ref><ref id="hanspub.20704-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Ming, Y., Chen, Z., Chen, L., et al. (2010) Ginsenoside Compound K Attenuates Metastatic Growth of Hepatocellular Carcinoma, Which Is Associated with the Translocation of Nuclear Factor-κB p65 and Reduction of Matrix Metalloproteinase-2/9. Planta Medica, 77, 428-433.&lt;br&gt; https://doi.org/10.1055/s-0030-1250454</mixed-citation></ref><ref id="hanspub.20704-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, Y., Bu, L., Yan, H., et al. (2009) 20S-Protopanaxadiol Inhibits P-Glycoprotein in Multidrug Resistant Cancer Cells. Planta Medica, 75, 1124-1128.&lt;br&gt; https://doi.org/10.1055/s-0029-1185477</mixed-citation></ref><ref id="hanspub.20704-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">明艳林, 郑志忠, 陈良华, 等. 20-O-β-D-吡喃葡萄糖苷-20(S)-原人参二醇对抗肝癌药物的增敏作用研究[J]. 中草药, 2010, 41(6): 935-938.</mixed-citation></ref><ref id="hanspub.20704-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">陈明侠, 徐华丽, 于小风, 等. 20(S)-原人参二醇的抗肿瘤及免疫调节作用研究[J]. 中国药师, 2007, 10(12): 65- 68.</mixed-citation></ref><ref id="hanspub.20704-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Kang, S., Kim, J.E., Song, N.R., et al. (2014) The Ginsenoside 20-O-β-D-Glucopyranosyl-20(S)-Protopanaxadiol Induces Autophagy and Apoptosis in Human Melanoma via AMPK/JNK Phosphorylation. PLoS ONE, 9, e104305.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0104305</mixed-citation></ref></ref-list></back></article>